Skip to main content
HRTX logo

Heron Therapeutics, Inc. (HRTX) Stock Price & Analysis

Heron Therapeutics, Inc. (HRTX) — MoonshotScore 24/100 (Weak band), calculated Nov 18, 2026. Price $0.2525 (-4.39%), as of the Nov 20, 2026 trading session; market cap $48.0M.

Educational signal · not a buy or sell recommendation · How to read this

$0.2525 −$0.0116 (-4.39%) Market Cap $48.0M

Heron Therapeutics, Inc. · HRTX · NASDAQ

Heron Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for unmet patient needs, utilizing its proprietary drug delivery technology. The company offers several products aimed at managing chemotherapy-induced nausea and pain management.

Price as of Nov 20, 2026

Key Statistics

24 of 100

MoonshotScore v2 · Heron Therapeutics (HRTX)

Weak
Business Quality Solid (64)
Financial Safety Fragile (7)
Valuation Full (47)
Growth Durability Fading (39)
Momentum Slipping (30)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fragile balance sheet, weak growth and a full valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Fading; Momentum: Slipping.

  • quarterly revenue $35M (Q3 FY2026, quarter ended Sep 30, 2026)
  • EPS beat 3 of the last 8 reports
  • Altman Z -10.74 · Piotroski F 3

Holding back: balance-sheet strain, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for HRTX (58 recorded, newest six shown)
RecordedScoreBand
24Weak
24Weak
24Weak
24Weak
24Weak
24Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.2525
Change on the day-4.39%
52-week range$0.2525 – $1.58
Market capitalisation$48.0M—
Price / earnings (trailing)2.49
Shares traded on the day1.75M

Price & events

Other perspectives

Council score for Heron Therapeutics (HRTX): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Negative
Valuation Neutral
Growth Durability Weak
Momentum Weak

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Unfavorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Oct 16, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Neutral
Debt/Equity Negative
ROE Negative
Gross Margin Strong

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Heron Therapeutics (HRTX), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Heron Therapeutics, Inc. (HRTX) is listed on NASDAQ. It employs 128 people and is led by Craig Alexander Collard. In Q3 FY2026 it reported revenue of $35M and net income of -$5M. The market values it at $48.0M.

2 · Latest results

What do the latest results show for Heron Therapeutics (HRTX)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $35M. Against analyst estimates the company has EPS beat 3 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$35M-$5M-$0.03 (diluted)
Q2 FY2026$38M-$5M-$0.03 (diluted)
Q1 FY2026$35M-$8M-$0.04 (diluted)
Q4 FY2025$41M-$3M-$0.02 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Heron Therapeutics (HRTX)?

Short answer · as of

What is holding it back is balance-sheet strain, weak price trend. The distress and quality screens read Altman Z -10.74 · Piotroski F 3. Trailing ratios: ROA -2.2% · current ratio 2.33.

Data-derived red flags

  • Listing risk — at $0.2525 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
  • Financial-distress signal — its Altman Z-Score of -10.74 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
5 · Peer comparison

How does Heron Therapeutics compare with its peers?

Short answer

Heron Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Regeneron Pharmaceuticals, Inc. (REGN) Named competitor$923.34 Nov 19, 2026$95.5B95 5-pillar Nov 18, 2026
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.45 Nov 19, 2026$475M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$8.76 Nov 20, 2026$521M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$2.90 Nov 20, 2026$245M90 5-pillar Nov 18, 2026
Bristol-Myers Squibb Company (BMY) Named competitor$58.80 Nov 20, 2026$120B85 5-pillar Nov 18, 2026
Amgen Inc. (AMGN) Named competitor$438.82 Nov 19, 2026$237B84 5-pillar Nov 18, 2026
Novartis AG (NVS) Named competitor$151.22 Nov 19, 2026$286B82 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.47 Nov 20, 2026$86.6M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$10.92 Nov 20, 2026$99.3M82 5-pillar Nov 18, 2026
Gilead Sciences, Inc. (GILD) Named competitor$166.53 Nov 19, 2026$207B72 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.69 Nov 19, 2026$160M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.84 Nov 20, 2026$174M69 5-pillar Nov 18, 2026
Heron Therapeutics (HRTX) — this page$0.2525$48.0M24

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held HRTX in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported HRTX in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Heron Therapeutics (HRTX)?

Read these with our analysis →

Investor Questions: HRTX Stock

These answers are editorial: 1 of these 9 answers is drawn from the HRTX research dossier (written May 10, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for HRTX?

HRTX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is HRTX a good stock to buy?

Stock Expert AI does not rate HRTX buy, sell or hold. Heron Therapeutics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the HRTX stock price today?

The last price recorded for Heron Therapeutics, Inc. (HRTX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for HRTX?

Heron Therapeutics faces several risks, including potential regulatory approval delays that could impede product launches. Competitive pressures from larger pharmaceutical firms pose a threat to market share, while changes in healthcare regulations could impact pricing strategies.

What are the key factors to evaluate for HRTX?

Heron Therapeutics, Inc. (HRTX) holds a MoonshotScore in the low range. To weigh it, start with the trailing P/E under Price & valuation on this page. No dividend yield as the company reinvests earnings into product development and clinical trials. Not financial advice.

How frequently does HRTX data refresh on this page?

HRTX's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven HRTX's recent stock price performance?

Heron Therapeutics, Inc. (HRTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative proprietary technology for drug delivery. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider HRTX overvalued or undervalued right now?

The trailing P/E of Heron Therapeutics, Inc. (HRTX) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of HRTX?

Fractional-share availability for Heron Therapeutics, Inc. (HRTX) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 16 figures on this page — 9 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.